{"id":13647,"date":"2023-01-16T10:46:40","date_gmt":"2023-01-16T09:46:40","guid":{"rendered":"https:\/\/udic.es\/?p=13647"},"modified":"2024-02-16T10:14:36","modified_gmt":"2024-02-16T09:14:36","slug":"farmac-nou-per-a-la-malaltia-dalzheimer","status":"publish","type":"post","link":"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/","title":{"rendered":"F\u00e0rmac nou per a la malaltia d&#8217;Alzheimer"},"content":{"rendered":"<p>El dia de Reis, l&#8217;administraci\u00f3 d&#8217;Alimentaci\u00f3 i Medicaments dels Estats Units va aprovar un f\u00e0rmac nou per a la malaltia d&#8217;Alzheimer en fase primerenca o per a pacients amb deteriorament cognitiu lleu. Aquest f\u00e0rmac, lecanemab, alenteix de manera moderada el ritme del declivi cognitiu de manera que \u00e9s perceptible per als pacients.<\/p>\n<p>L&#8217;Hospital Universitari General de Catalunya, a trav\u00e9s de la Unitat de Recerca Cl\u00ednica (UDIC) liderada pel Dr. Ernest Balaguer, ha participat a l&#8217;assaig d&#8217;aquest medicament en fase 2 i fase 3. En totes dues tenim pacients que reben obert la medicaci\u00f3 des de fa anys.<\/p>\n<p>El lecanemab es comercialitza amb el nom de Leqembi i ha estat desenvolupat per les companyies Esai i Biogen. A la tercera fase d&#8217;experimentaci\u00f3 cl\u00ednica es va observar que el medicament va aconseguir un alentiment en declivi cognitiu del 27% despr\u00e9s de 18 mesos.<\/p>\n<p class=\"p1\"><span class=\"s1\">Leqembi elimina els agregats insolubles de la prote\u00efna beta amiloide, els pacients que van rebre aquest tractament van registrar una significativa reducci\u00f3 de la placa beta amiloide, demostrada al PET amiloide. L&#8217;acumulaci\u00f3 de beta amiloide al cervell \u00e9s precursora de la malaltia d&#8217;Alzheimer.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>El dia de Reis, l&#8217;administraci\u00f3 d&#8217;Alimentaci\u00f3 i Medicaments dels Estats Units va aprovar un f\u00e0rmac nou per a la malaltia d&#8217;Alzheimer en fase primerenca o per a pacients amb deteriorament cognitiu lleu. Aquest f\u00e0rmac, lecanemab, alenteix de manera moderada el ritme del declivi cognitiu de manera que \u00e9s perceptible per als pacients. L&#8217;Hospital Universitari General&#8230;<\/p>\n","protected":false},"author":2,"featured_media":9344,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[106,131,133],"tags":[],"class_list":["post-13647","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-alzeimer-ca","category-alzeimer-ca-2","category-novetats"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>F\u00e0rmac nou per a la malaltia d&#039;Alzheimer - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica<\/title>\n<meta name=\"description\" content=\"El dia de Reis, l&#039;administraci\u00f3 d&#039;Alimentaci\u00f3 i Medicaments dels Estats Units va aprovar un f\u00e0rmac nou per a la malaltia d&#039;Alzheimer en fase primerenca o\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"F\u00e0rmac nou per a la malaltia d&#039;Alzheimer - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"og:description\" content=\"El dia de Reis, l&#039;administraci\u00f3 d&#039;Alimentaci\u00f3 i Medicaments dels Estats Units va aprovar un f\u00e0rmac nou per a la malaltia d&#039;Alzheimer en fase primerenca o\" \/>\n<meta property=\"og:url\" content=\"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/\" \/>\n<meta property=\"og:site_name\" content=\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-16T09:46:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-16T09:14:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"5056\" \/>\n\t<meta property=\"og:image:height\" content=\"1752\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tito Surribas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tito Surribas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/\"},\"author\":{\"name\":\"Tito Surribas\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e\"},\"headline\":\"F\u00e0rmac nou per a la malaltia d&#8217;Alzheimer\",\"datePublished\":\"2023-01-16T09:46:40+00:00\",\"dateModified\":\"2024-02-16T09:14:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/\"},\"wordCount\":195,\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"image\":{\"@id\":\"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg\",\"articleSection\":[\"Alzeimer\",\"Alzeimer\",\"Novetats\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/\",\"url\":\"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/\",\"name\":\"F\u00e0rmac nou per a la malaltia d'Alzheimer - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg\",\"datePublished\":\"2023-01-16T09:46:40+00:00\",\"dateModified\":\"2024-02-16T09:14:36+00:00\",\"description\":\"El dia de Reis, l'administraci\u00f3 d'Alimentaci\u00f3 i Medicaments dels Estats Units va aprovar un f\u00e0rmac nou per a la malaltia d'Alzheimer en fase primerenca o\",\"breadcrumb\":{\"@id\":\"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/#primaryimage\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg\",\"width\":5056,\"height\":1752,\"caption\":\"Area privada5\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/udic.es\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"F\u00e0rmac nou per a la malaltia d&#8217;Alzheimer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/udic.es\/#website\",\"url\":\"https:\/\/udic.es\/\",\"name\":\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"description\":\"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/udic.es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/udic.es\/#organization\",\"name\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"url\":\"https:\/\/udic.es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"width\":408,\"height\":123,\"caption\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\"},\"image\":{\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e\",\"name\":\"Tito Surribas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g\",\"caption\":\"Tito Surribas\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"F\u00e0rmac nou per a la malaltia d'Alzheimer - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"El dia de Reis, l'administraci\u00f3 d'Alimentaci\u00f3 i Medicaments dels Estats Units va aprovar un f\u00e0rmac nou per a la malaltia d'Alzheimer en fase primerenca o","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/","og_locale":"ca_ES","og_type":"article","og_title":"F\u00e0rmac nou per a la malaltia d'Alzheimer - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","og_description":"El dia de Reis, l'administraci\u00f3 d'Alimentaci\u00f3 i Medicaments dels Estats Units va aprovar un f\u00e0rmac nou per a la malaltia d'Alzheimer en fase primerenca o","og_url":"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/","og_site_name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","article_publisher":"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/","article_published_time":"2023-01-16T09:46:40+00:00","article_modified_time":"2024-02-16T09:14:36+00:00","og_image":[{"width":5056,"height":1752,"url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg","type":"image\/jpeg"}],"author":"Tito Surribas","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"Tito Surribas","Temps estimat de lectura":"2 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/#article","isPartOf":{"@id":"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/"},"author":{"name":"Tito Surribas","@id":"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e"},"headline":"F\u00e0rmac nou per a la malaltia d&#8217;Alzheimer","datePublished":"2023-01-16T09:46:40+00:00","dateModified":"2024-02-16T09:14:36+00:00","mainEntityOfPage":{"@id":"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/"},"wordCount":195,"publisher":{"@id":"https:\/\/udic.es\/#organization"},"image":{"@id":"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg","articleSection":["Alzeimer","Alzeimer","Novetats"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/","url":"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/","name":"F\u00e0rmac nou per a la malaltia d'Alzheimer - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","isPartOf":{"@id":"https:\/\/udic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/#primaryimage"},"image":{"@id":"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg","datePublished":"2023-01-16T09:46:40+00:00","dateModified":"2024-02-16T09:14:36+00:00","description":"El dia de Reis, l'administraci\u00f3 d'Alimentaci\u00f3 i Medicaments dels Estats Units va aprovar un f\u00e0rmac nou per a la malaltia d'Alzheimer en fase primerenca o","breadcrumb":{"@id":"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/#primaryimage","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg","width":5056,"height":1752,"caption":"Area privada5"},{"@type":"BreadcrumbList","@id":"https:\/\/udic.es\/ca\/farmac-nou-per-a-la-malaltia-dalzheimer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/udic.es\/ca\/"},{"@type":"ListItem","position":2,"name":"F\u00e0rmac nou per a la malaltia d&#8217;Alzheimer"}]},{"@type":"WebSite","@id":"https:\/\/udic.es\/#website","url":"https:\/\/udic.es\/","name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","publisher":{"@id":"https:\/\/udic.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/udic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/udic.es\/#organization","name":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","url":"https:\/\/udic.es\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","width":408,"height":123,"caption":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica"},"image":{"@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/"]},{"@type":"Person","@id":"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e","name":"Tito Surribas","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/udic.es\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g","caption":"Tito Surribas"}}]}},"_links":{"self":[{"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/posts\/13647"}],"collection":[{"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/comments?post=13647"}],"version-history":[{"count":2,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/posts\/13647\/revisions"}],"predecessor-version":[{"id":13651,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/posts\/13647\/revisions\/13651"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/media\/9344"}],"wp:attachment":[{"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/media?parent=13647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/categories?post=13647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/tags?post=13647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}